VEGFA and Parkinson disease: On increasing the specificity of the suspected events by conducting analyses at the level of PT, a trend of disproportionality among persons of all ages emerged for one intravitreal anti-VEGF drug and “Parkinson’s disease”, specifically ranibizumab, with a PRR of 3.11 (95% CI: 1.39–6.94) concerning N=6 ICSRs.